California-based biotech Cytokinetcs (NASDAQ: CYTK) finished the trading week in style, as its stock price outperformed many other titles by rising nearly 5% on Friday. News of a fresh licensing deal in...
This week, Pfizer PFE issued its financial guidance for 2025. Sanofi SNY and Teva Pharmaceutical’s TEVA inflammatory bowel disease (IBD) study on their candidate, duvakitug (TEV’574), met its primary...
Merck MRK announced that the FDA has accepted the biologics license application (BLA) for its investigational prophylactic long-acting monoclonal antibody, clesrovimab (MK-1654), designed to protect infants...
Sanofi SNY and partner Teva Pharmaceuticals TEVA announced positive data from the phase IIb RELIEVE UCCD study on their investigational anti-TL1A therapy, duvakitug (formerly TEV’574), for the treatment...
Investors are now eyeing duvakitug’s potential to become a significant revenue driver for both companies, especially as there is currently no cure for IBD.
Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 15.5% in the year so far compared with the industry’s decline of 6.3%.The stock has underperformed the sector and the S&P 500 Index during...
GSK GSK stock has declined 20.2% in the past three months compared with a decrease of 12.3% for the industry. The stock has also underperformed the sector and the S&P 500 index, as seen in the chart below....
Many companies that performed well in the early pandemic years have since fallen off the radar or at least have seen their shares drop substantially during the past three years. Telemedicine Teladoc Health...
/Pfizer%20Inc_%20logo%20on%20iPad-by%20Koshiro%20K%20via%20Shutterstock.jpg)
Despite Pfizer's underperformance relative to the healthcare sector, Wall Street analysts remain moderately optimistic about the stock’s prospects.
Discover 2 compelling AI stocks NVIDIA (NASDAQ: NVDA) has invested in. Learn how the AI leader's vision can guide your portfolio in the tech revolution.